Lannett Confident Of $1bn In Sales By 2025

Lantus And Advair Among Key Projects

 
• By Dean Rudge

US-centric generics player Lannett has an ambitious sales and profitability goals for the next five years, driven by several rewarding pipeline opportunities and a leaner cost base. CEO Tim Crew told investors of Lannett’s plans as he presented year-end financial results

US-Money-and-Pills_V2_1200x675
Complex dosage forms via partnerships are driving Lannett towards growth in the future • Source: Shutterstock

Lucrative product opportunities in the US, including a biosimilar to Lantus (insulin glargine) with China’s HEC group and generic Advair (fluticasone/salmeterol) with Respirent Pharmaceuticals, continue to drive Lannett Company, Inc’s. expectations of achieving annual sales of $1bn by 2025, says CEO Tim Crew.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business